Tacrolimus enema for left-sided ulcerative colitis
Part of Digestive system clinical trials.
This trial tests a liquid form of tacrolimus given as an enema to treat mild to moderate ulcerative colitis that affects the left side of the colon. It is for people who have not gotten enough relief from standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have mild to moderate ulcerative colitis that is limited to the left side of your colon (about the last 60 cm).
- Your disease is active despite trying at least one standard treatment like mesalamine, steroids, or other immune-suppressing drugs.
- You have not had a good response to biologics (like anti-TNF drugs) or you have stopped them for a washout period.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
- You are generally healthy with normal kidney, liver, and blood counts, and you have no serious other medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral study drug called Hemay005 for people with moderate to severe ulcerative colitis (UC) who have not responded well to other treatments. If you join, you will receive either the study drug or a placebo (inactive pill) to see if it helps reduce symptoms and heal the gut lining.
This trial tests a new medicine, ENC1018, taken by mouth, for people with moderate to severe ulcerative colitis (UC) that hasn't improved with standard treatments. The goal is to see if it's safe and helps reduce symptoms.
This trial tests a new oral medication for people with active ulcerative colitis that hasn't responded well to standard treatments. The goal is to see if the drug reduces inflammation and improves symptoms.
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
This trial tests fecal microbiota transplantation (a procedure that puts healthy donor bacteria into your gut) for left-sided ulcerative colitis. It compares results using donors from two different backgrounds to see if one works better.
This study looks at whether it is safe to stop taking an immunosuppressant medication in older adults (60+) with ulcerative colitis that has been in remission for a long time. By stopping the drug, they hope to reduce side effects while keeping the disease under control.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.